Total Payments
$3,158
2024 Payments
$238.02
Companies
31
Transactions
69
Medicare Patients
1,663
Medicare Billing
$284,052
Payment Breakdown by Category
Food & Beverage$2,024 (64.1%)
Research$1,040 (32.9%)
Education$93.59 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,024 | 63 | 64.1% |
| Unspecified | $1,040 | 1 | 32.9% |
| Education | $93.59 | 5 | 3.0% |
Payments by Type
General
$2,117
68 transactions
Research
$1,040
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1,040 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $200.99 | 3 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $198.99 | 8 | $0 (2021) |
| Galvanize Therapeutics, Inc | $156.27 | 1 | $0 (2023) |
| Amgen Inc. | $142.63 | 6 | $0 (2020) |
| Janssen Biotech, Inc. | $137.18 | 4 | $0 (2024) |
| Incyte Corporation | $132.66 | 3 | $0 (2018) |
| Gilead Sciences, Inc. | $132.18 | 2 | $0 (2022) |
| BeiGene USA, Inc. | $95.11 | 1 | $0 (2021) |
| PFIZER INC. | $89.83 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $238.02 | 8 | Janssen Biotech, Inc. ($82.72) |
| 2023 | $432.78 | 8 | Galvanize Therapeutics, Inc ($156.27) |
| 2022 | $200.55 | 7 | Gilead Sciences, Inc. ($72.14) |
| 2021 | $1,225 | 8 | Eli Lilly and Company ($1,040) |
| 2020 | $123.85 | 5 | Amgen Inc. ($88.61) |
| 2019 | $176.71 | 3 | E.R. Squibb & Sons, L.L.C. ($91.62) |
| 2018 | $460.15 | 15 | Incyte Corporation ($115.91) |
| 2017 | $300.38 | 15 | Novartis Pharmaceuticals Corporation ($66.59) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $82.72 | General |
| Category: Oncology | ||||||
| 09/12/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: ONCOLOGY | ||||||
| 07/05/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 06/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/22/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $16.47 | General |
| 05/15/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: BioOncology | ||||||
| 02/07/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/30/2023 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $79.03 | General |
| 11/16/2023 | Galvanize Therapeutics, Inc | ALIYA SYSTEM (Device) | Food and Beverage | In-kind items and services | $156.27 | General |
| Category: PULSED ELECTRIC FIELD | ||||||
| 10/04/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Oncology | ||||||
| 09/21/2023 | PFIZER INC. | BOSULIF (Drug), ELREXFIO | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/06/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $80.94 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/24/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: Oncology | ||||||
| 06/22/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $34.93 | General |
| Category: ONCOLOGY | ||||||
| 05/05/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $27.49 | General |
| 12/01/2022 | Puma Biotechnology, Inc. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.71 | General |
| Category: Hematology | ||||||
| 05/05/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $72.14 | General |
| Category: ONC | ||||||
| 04/28/2022 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $15.89 | General |
| 04/19/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.93 | General |
| Category: Hematology | ||||||
| 01/10/2022 | EMD Serono, Inc. | — | Education | In-kind items and services | $43.80 | General |
| 12/16/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2021 | Eli Lilly and Company | — | — | In-kind items and services | $1,040.32 | Research |
| Study: EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $1,040 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 380 | 667 | $124,537 | $59,925 |
| 2022 | 4 | 396 | 764 | $135,864 | $69,513 |
| 2021 | 6 | 473 | 924 | $159,755 | $85,436 |
| 2020 | 4 | 414 | 877 | $154,596 | $69,178 |
Total Patients
1,663
Total Services
3,232
Medicare Billing
$284,052
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 119 | 345 | $71,585 | $36,667 | 51.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 170 | 221 | $33,715 | $15,024 | 44.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 52 | 52 | $16,014 | $7,083 | 44.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 39 | 49 | $3,223 | $1,151 | 35.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 147 | 437 | $85,910 | $46,740 | 54.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 150 | 205 | $29,287 | $13,904 | 47.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 55 | 55 | $16,491 | $7,282 | 44.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 44 | 67 | $4,176 | $1,588 | 38.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 168 | 521 | $95,616 | $55,446 | 58.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 187 | 268 | $36,920 | $18,809 | 50.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 42 | 42 | $11,709 | $5,808 | 49.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 16 | $8,870 | $2,440 | 27.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 48 | 64 | $3,840 | $1,577 | 41.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 13 | 13 | $2,800 | $1,357 | 48.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 186 | 586 | $105,012 | $48,567 | 46.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 157 | 220 | $27,635 | $11,547 | 41.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 59 | 59 | $15,797 | $7,171 | 45.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $6,152 | $1,893 | 30.8% |
About Amir Anis
Amir Anis is a Hematology & Oncology healthcare provider based in Joplin, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598859084.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amir Anis has received a total of $3,158 in payments from pharmaceutical and medical device companies, with $238.02 received in 2024. These payments were reported across 69 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($2,024).
As a Medicare-enrolled provider, Anis has provided services to 1,663 Medicare beneficiaries, totaling 3,232 services with total Medicare billing of $284,052. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Joplin, MO
- Active Since 10/02/2006
- Last Updated 10/22/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1598859084
Products in Payments
- OPDIVO (Biological) $187.00
- ALIYA SYSTEM (Device) $156.27
- JAKAFI (Drug) $132.66
- BRUKINSA (Drug) $95.11
- KISQALI (Drug) $85.89
- ERLEADA (Drug) $82.72
- LifeVest (Device) $80.94
- Trodelvy (Drug) $72.14
- Kyprolis (Drug) $68.64
- Zydelig (Drug) $60.04
- Neulasta (Biological) $39.43
- IBRANCE (Drug) $36.99
- VENCLEXTA (Drug) $34.93
- IMFINZI (Biological) $34.32
- KEYTRUDA (Biological) $34.12
- PROMACTA (Drug) $33.77
- PROVENGE (Drug) $29.85
- BRAFTOVI (Drug) $29.57
- Columvi (Biological) $28.72
- Zelboraf (Biological) $27.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Joplin
Dr. Anisa Hassan, M.d, M.D
Hematology & Oncology — Payments: $14,208
Hematology & Oncology $14,208
Matthew Miller, D.o, D.O
Hematology & Oncology — Payments: $7,036
Hematology & Oncology $7,036
Regine Leconte, M.d, M.D
Hematology & Oncology — Payments: $6,937
Hematology & Oncology $6,937
Dr. Kerry Williams-Wuch, M.d, M.D
Hematology & Oncology — Payments: $3,800
Hematology & Oncology $3,800
Samir Dalia, Md, MD
Hematology & Oncology — Payments: $3,276
Hematology & Oncology $3,276
Dr. Pamela Landon, M.d, M.D
Hematology & Oncology — Payments: $2,717
Hematology & Oncology $2,717